Atopic Dermatitis

Researchers not only confirmed the rapid and sustained efficacy of the drug, but also observed an increased onset of action for children under 6.

Patrick Burnett, MD, PhD, provides insights into the significance of Arcutis’ roflumilast cream 0.15% formulation and its impact on pediatric patients.

Click here to answer today's poll and read more about OX40 treatment for atopic dermatitis.

The planned PDUFA data was July 7, 2024.

Lawrence Eichenfield, MD, provides insights into the clinical implications of topical ruxolitinib cream for atopic dermatitis and treatment patterns.

The study, which represents the first human trial of hcMSCs for AD, found the treatment was associated with “significant” improvements in symptoms.

Matthew Zirwas, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving intense itch and severe hand dermatitis.

Robert Bruce Posnick, MD, examines a case of a 55-year-old female patient with a 50-year history of atopic dermatitis, comorbid asthma, and severe alopecia areata, presenting with recurrent patches throughout her body, predominantly affecting her face, hands, trunk, arms, legs, and eyelids.

Robert Bruce Posnick, MD, presents a case study of a 13-year-old Indian male student with an 11-year history of moderate atopic dermatitis, characterized by hyperpigmented excoriated patches covering 6% of his body surface area, primarily affecting the wrists, arms, legs, face, and neck.

Experts on atopic dermatitis weigh the risks and rewards of systemic treatments for pregnant patients and provide clinical insights on monitoring for adverse effects associated with dupilumab.

Drs Kiracofe and Murase provide clinical insights on treatment escalation practices for patients with atopic dermatitis who are pregnant.

Recent research and conversations shared at the National Eczema Association expo tackled the link between patient well-being and eczema.

Mona Shahriari, MD, analyzes the case of a 35-year-old male patient presenting with erythematous patches on his trunk and arms, who was diagnosed with moderate atopic dermatitis at age 2 but experienced improvement through adolescence and adulthood.

A medical expert in dermatology examines comprehensive treatment approaches for atopic dermatitis in a 12-year-old African American female patient, focusing on the assessment of topical and non-steroidal therapeutic options.

Mona Shahriari, MD, presents a case study of a 12-year-old African American girl experiencing an intensely pruritic rash predominantly affecting the bilateral antecubital and popliteal fossae.

A new report delves into the case of a 35-year-old man with ARPC and why dupilumab was utilized for treatment.

James Song, MD, shares a comprehensive guide to what is new, what is now, and what is next in AD treatment.

Mickey Bryson describes the impact of atopic dermatitis on his quality of life and family, and the session concludes with final reflections.

A recent study demonstrated the benefits and limitations of PatientsLikeMe for patients with atopic dermatitis and other skin conditions.

A dermatology expert reviews findings from a recently presented study on using other atopic dermatitis (AD) treatments within six months of initiating ruxolitinib cream. The expert assesses ruxolitinib's effectiveness and potential role in treatment, highlighting the need for further research on its long-term implications in AD management.

Bradley Burnam discusses results from an in-vivo model of atopic dermatitis.

Focusing on pregnant patients with atopic dermatitis who are treatment naïve, Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, discuss best practices for informing patients on the available treatment options for this condition.

Jenny Murase, MD, provides a brief overview of the Fc receptor and the role of transcription binding in atopic dermatitis.

Ensemble No.2, or ENS-002, is an investigational live biotherapeutic product first detected by Concerto Biosciences using its kChip technology.

Authorization for Eli Lilly's Ebglyss is based on positive results from the ADvocate 1, ADvocate 2, and ADhere studies.